Previously, we have shown that 90% of AML patients express at least one of the LAAs WT1, survivin, and TERT and that their bone marrow (BM) levels are 13.8–86.7-fold higher compared with normal donors [5]. This evidence concerns the gene TERT and acute myeloid leukemia.